New NHS Weight Loss Treatment – Tirzepatide (Mounjaro)

Posted by: markh - Posted on:

You may have seen in the media that from 23 June 2025, some GP practices can begin offering a new NHS treatment called Tirzepatide (Mounjaro).

Tirzepatide (Mounjaro) is to help people with obesity lose weight and help with weight related health problems.

This does not mean the medicine will be prescribed straight away or available immediately. This treatment is also only available to people who have certain medical conditions.

We are experiencing a lot of enquiries about this. Please be patient with us while the NHS rolls out this treatment safely and fairly.

You can find lots of useful information about Tirzepatide (Mounjaro) here ICB advice and support weight loss drugs information for patients. This includes details about who is eligible and other options to support you with weight loss.

Who can get this treatment? Tirzepatide will only be offered to people who have the highest clinical need, this means those whose health is most affected by obesity and who are likely to benefit the most.

To be considered for this treatment, you must:

  • Have a Body Mass Index (BMI) of 40 or more, and

Have at least four of the following health conditions:

  • High blood pressure
  • High cholesterol or high fat levels in the blood
  • Sleep apnoea (trouble breathing while asleep)
  • Heart Disease
  • Type 2 Diabetes

Important things to know

You will need a full clinical assessment.

Tirzepatide (Mounjaro) will only be given as part of a full NHS care plan. This includes referral to wrap around care programme to support with healthy eating and lifestyle changes.

You can read more in the official NHS weight loss treatment guidance.